New immunotherapy before surgery for multiple cancer types
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial tests new immunotherapy combinations given before surgery for cancers that have certain genetic features (dMMR or pMMR). It aims to see if these drugs can shrink tumors and improve outcomes for patients with various cancer types, including those for which standard neoadjuvant therapy is not an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a newly diagnosed cancer that is either dMMR or pMMR and is one of the types listed (like sarcoma, head and neck, anal, or esophageal cancer) or in another group.
- Your cancer has not spread to other parts of the body (non-metastatic).
- You are healthy enough for daily activities (WHO performance status 0 or 1).
- You have adequate blood counts and organ function as shown by recent lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (botensilimab and balstilimab) given before surgery for early-stage rectal cancer that is MSS/pMMR. The goal is to see if this treatment can shrink the tumor and improve outcomes compared to standard care.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can help shrink stomach cancer and reduce the chance of it coming back. It is for people whose tumors have a specific genetic feature called MSI-H or dMMR, which often responds well to immunotherapy.
This trial tests two immunotherapy drugs (botensilimab and balstilimab) given before surgery to treat advanced colorectal cancer that can be removed. The goal is to help the immune system fight cancer cells and improve outcomes after surgery.
This trial tests the combination of two immunotherapy drugs (botensilimab and balstilimab) plus targeted radiation to liver tumors. It's for people with colorectal cancer that has spread and hasn't responded to standard treatments.
This study tests giving an immunotherapy drug (pembrolizumab) before surgery for people with early-stage colon cancer that has a specific genetic feature. The goal is to see if the drug can shrink the tumor enough to avoid more extensive surgery.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Resectable MMR-deficient Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.